Top

Published in:

01-02-2016 | Original Article

Circulating levels of the miRNAs, miR-194, and miR-29b, as clinically useful biomarkers for colorectal cancer

Authors: Gholam Basati, Amirnader Emami Razavi, Iraj Pakzad, Fardin Ali Malayeri

Published in: Tumor Biology | Issue 2/2016

Abstract

The microRNAs (miRNAs), miR-194 and miR-29b, have been shown to downregulate in colorectal cancer (CRC) and may identify and classify CRC patients as compared with those in control subjects. In the current study, we aimed to explore whether the serum levels of the miRNAs could be potential biomarkers for diagnosis and prognosis of CRC. A quantitative reverse-transcription polymerase chain reaction (qRT-PCR) assay was utilized to determine and compare serum levels of miR-194 and miR-29b in 55 patients with CRC and 55 control subjects. The correlations between levels of the miRNAs and clinicopathological stages of cancer were analyzed in patients. Receiver operating characteristic (ROC) curve and survival analyses were carried out, respectively, to determine diagnostic and prognostic values of the miRNAs. Serum levels of miR-194 and miR-29b were found to be significantly lower in CRC patients than those in control subjects (P < 0.0001). Moreover, serum levels of the miRNAs in patients were inversely correlated with the advanced TNM stages (P = 0.01). ROC curve and survival analyses revealed that reduced levels of the miRNAs could serve as diagnostic and prognostic biomarkers for patients with CRC (P = 0.0001). Serum levels of miR-194 and miR-29b may serve as potential biomarkers for diagnosis and prognosis of CRC.

Max Parkin D, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74.CrossRefPubMed

Narayanan V, Peppelenbosch MP, Konstantinov SR. Human fecal microbiome-based biomarkers for colorectal cancer. Cancer Prev Res. 2014;7(11):1108–11.CrossRef

Schetter AJ, Okayama H, Harris CC. The role of microRNAs in colorectal cancer. Cancer J Sudbury Mass. 2012;18(3):244.CrossRef

Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136(2):215–33.CrossRefPubMedPubMedCentral

Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci. 2008;105(30):10513–8.CrossRefPubMedPubMedCentral

Blanco-Calvo M, Calvo L, Figueroa A, Haz-Conde M, Antón-Aparicio L, Valladares-Ayerbes M. Circulating microRNAs: molecular microsensors in gastrointestinal cancer. Sensors. 2012;12(7):9349–62.CrossRefPubMedPubMedCentral

Selth L, Townley S, Bert A, Stricker P, Sutherland P, Horvath L, et al. Circulating microRNAs predict biochemical recurrence in prostate cancer patients. Br J Cancer. 2013;109(3):641–50.CrossRefPubMedPubMedCentral

Zhai H, Karaayvaz M, Dong P, Sakuragi N, Ju J. Prognostic significance of miR-194 in endometrial cancer. Biomark Res. 2013;1(12):10.1186.

White NM, Bao TT, Grigull J, Youssef YM, Girgis A, Diamandis M, et al. miRNA profiling for clear cell renal cell carcinoma: biomarker discovery and identification of potential controls and consequences of miRNA dysregulation. J Urol. 2011;186(3):1077–83.CrossRefPubMed

10.

Chiang Y, Song Y, Wang Z, Liu Z, Gao P, Liang J, et al. microRNA-192, -194 and -215 are frequently downregulated in colorectal cancer. Exp Ther Med. 2012;3(3):560–6.PubMed

11.

Zhao H-J, Ren L-L, Wang Z-H, Sun T-T, Yu Y-N, Wang Y-C, et al. MiR-194 deregulation contributes to colorectal carcinogenesis via targeting AKT2 pathway. Theranostics. 2014;4(12):1193.CrossRefPubMedPubMedCentral

12.

Xiao L, Rao JN, Zou T, Liu L, Cao S, Martindale JL, et al. miR-29b represses intestinal mucosal growth by inhibiting translation of cyclin-dependent kinase 2. Mol Biol Cell. 2013;24(19):3038–46.CrossRefPubMedPubMedCentral

13.

Poudyal D, Cui X, Le PM, Hofseth AB, Windust A, Nagarkatti M, et al. A key role of microRNA-29b for the suppression of colon cancer cell migration by American ginseng. PLoS One. 2013;8(10):e75034.CrossRefPubMedPubMedCentral

14.

Zhang K, Zhang C, Liu L, Zhou J. A key role of microRNA-29b in suppression of osteosarcoma cell proliferation and migration via modulation of VEGF. Int J Clinical Exp Pathol. 2014;7(9):5701.

15.

Fleming I, Cooper J, Henson D, Hutter R, Kennedy B, Murphy G et al. American Joint Committee on Cancer. AJCC cancer staging manual. 5. Lippincott-Raven, Philadelphia; 1997.

16.

Yamada A, Cox MA, Gaffney KA, Moreland A, Boland CR, Goel A. Technical factors involved in the measurement of circulating microRNA biomarkers for the detection of colorectal neoplasia. PLoS One. 2014;9(11):e112481.CrossRefPubMedPubMedCentral

17.

Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2− ΔΔCT method. methods. 2001;25(4):402-8.

18.

Dong P, Kaneuchi M, Watari H, Hamada J, Sudo S, Ju J, et al. MicroRNA-194 inhibits epithelial to mesenchymal transition of endometrial cancer cells by targeting oncogene BMI-1. Mol Cancer. 2011;10:99.CrossRefPubMedPubMedCentral

19.

Khella HW, Bakhet M, Allo G, Jewett MA, Girgis AH, Latif A, et al. miR-192, miR-194 and miR-215: a convergent microRNA network suppressing tumor progression in renal cell carcinoma. Carcinogenesis. 2013;34(10):2231–9.CrossRefPubMed

20.

Kahlert C, Lahes S, Radhakrishnan P, Dutta S, Mogler C, Herpel E, et al. Overexpression of ZEB2 at the invasion front of colorectal cancer is an independent prognostic marker and regulates tumor invasion in vitro. Clin Cancer Res. 2011;17(24):7654–63.CrossRefPubMed

21.

Polański R, Warburton HE, Ray-Sinha A, Devling T, Pakula H, Rubbi CP, et al. MDM2 promotes cell motility and invasiveness through a RING-finger independent mechanism. FEBS Lett. 2010;584(22):4695–702.CrossRefPubMed

22.

Rose MG, Farrell MP, Schmitz JC. Thymidylate synthase: a critical target for cancer chemotherapy. Clin Colorectal Cancer. 2002;1(4):220–9.CrossRefPubMed

23.

Hino K, Tsuchiya K, Fukao T, Kiga K, Okamoto R, Kanai T, et al. Inducible expression of microRNA-194 is regulated by HNF-1α during intestinal epithelial cell differentiation. RNA. 2008;14(7):1433–42.CrossRefPubMedPubMedCentral

24.

Braun CJ, Zhang X, Savelyeva I, Wolff S, Moll UM, Schepeler T, et al. p53-responsive microRNAs 192 and 215 are capable of inducing cell cycle arrest. Cancer Res. 2008;68(24):10094–104.CrossRefPubMedPubMedCentral

25.

Santanam U, Zanesi N, Efanov A, Costinean S, Palamarchuk A, Hagan JP, et al. Chronic lymphocytic leukemia modeled in mouse by targeted miR-29 expression. Proc Natl Acad Sci. 2010;107(27):12210–5.CrossRefPubMedPubMedCentral

26.

Zhang Y, Li M, Wang H, Fisher WE, Lin PH, Yao Q, et al. Profiling of 95 microRNAs in pancreatic cancer cell lines and surgical specimens by real-time PCR analysis. World J Surg. 2009;33(4):698–709.CrossRefPubMedPubMedCentral

27.

Ru P, Steele R, Newhall P, Phillips NJ, Toth K, Ray RB. miRNA-29b suppresses prostate cancer metastasis by regulating epithelial–mesenchymal transition signaling. Mol Cancer Ther. 2012;11(5):1166–73.CrossRefPubMed

28.

Mott JL, Kobayashi S, Bronk SF, Gores GJ. mir-29 regulates Mcl-1 protein expression and apoptosis. Oncogene. 2007;26(42):6133–40.CrossRefPubMedPubMedCentral

29.

Garzon R, Volinia S, Liu C-G, Fernandez-Cymering C, Palumbo T, Pichiorri F, et al. MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood. 2008;111(6):3183–9.CrossRefPubMedPubMedCentral

30.

Akira Inoue, Hirofumi Yamamoto, Mamoru Uemura, Junichi Nishimura,Taishi Hata, Ichiro Takemasa, et al. MicroRNA-29b is a novel prognostic marker in colorectal cancer. Ann Surg Oncol. DOI 10.1245/s10434-014-4255-8

31.

Zheng J, Yu F, Dong P, Bai Y, Chen B. Expression of miRNA-29b and its clinical significances in primary hepatic carcinoma. Zhonghua yi xue za zhi. 2013;93(12):888–91.PubMed

32.

Wang Q, Huang Z, Ni S, et al. Plasma miR-601 and miR-760 are novel biomarkers for the early detection of colorectal cancer. PLoS One. 2012;7:e44398.CrossRefPubMedPubMedCentral

33.

Wang J, S-k H, Zhao M, Yang M, J-l Z, et al. Identification of a circulating microRNA signature for colorectal cancer detection. PLoS One. 2014;9(4):e87451. doi:10.1371/journal.pone.0087451.CrossRefPubMedPubMedCentral

Title: Circulating levels of the miRNAs, miR-194, and miR-29b, as clinically useful biomarkers for colorectal cancer
Authors: Gholam Basati
Amirnader Emami Razavi
Iraj Pakzad
Fardin Ali Malayeri
Publication date: 01-02-2016
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 2/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-015-3967-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2016

TRIM37 promoted the growth and migration of the pancreatic cancer cells

Perspective: Cooperation of Nanog, NF-κΒ, and CXCR4 in a regulatory network for directed migration of cancer stem cells

The chemokines CCR1 and CCRL2 have a role in colorectal cancer liver metastasis

The study of MED12 gene mutations in uterine leiomyomas from Iranian patients

Propensity score-based comparison of hepatic resection and transarterial chemoembolization for patients with advanced hepatocellular carcinoma

Predicting the molecular role of MEIS1 in esophageal squamous cell carcinoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer